Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia

MLL重排白血病癌基因沉默的表观遗传机制

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Although epigenetic dysregulation is already recognized to play an important role in the initiation and progression of many types of cancers, studies on epigenetic cancer therapy have been primarily focused on targeting a single epigenetic regulator to disrupt the maintenance of the disease. The cross-talks between epigenetic pathways that dictate gene expression/silencing and therapeutic outcome are just beginning to gain recognition. This application has immediate clinical relevance since DOT1L inhibitors are now in clinical trials for individuals with MLL-r leukemia. Important clinical responses have been noted with DOT1L inhibitor treatment alone, but there is no doubt that combination approaches will be necessary. The objective in this application is to determine the critical epigenetic effectors and mechanisms that establish oncogene silencing in MLL-r leukemia upon DOT1L inhibition. Preliminary studies based on a genome-scale RNAi screen have identified an essential role of histone deacetylase Sirtuin 1 (SIRT1) in silencing DOT1L-dependent oncogenes in MLL-AF9 leukemia (published in Nature Medicine). This proposed study will further utilize genome-wide genetic and epigenetic research tools to dissect the epigenetic mechanisms underlying the expression and silencing of oncogenes in both MLL-r leukemia and normal hematopoiesis. The proposed application is INNOVATIVE, in our opinion, because it introduces a novel concept of combinational targeting that simultaneously "induces" and "stabilizes" epigenetic silencing for profound oncogene suppression. In addition, this research will be of SIGNIFICANCE because it immediately provides novel therapeutic opportunities against the difficult-to-treat MLL-r leukemias by simultaneously activating the oncogene silencing mechanisms. The Specific Aims of this proposal are: 1. Examine the direct effect of SIRT1 enzymatic activity on silencing DOT1L-driven oncogenes in MLL-r leukemia. 2. Evaluate the efficacy of SIRT1 and DOT1L combinational targeting as a novel therapeutic strategy against MLL-r leukemia. 3. Investigate the role of SIRT1 in silencing DOT1L-dependent genes in hematopoietic stem/progenitor cells. Dr. Chun-Wei David Chen is currently a Senior Research Scientist in the Department of Cancer Biology and Genetics at Memorial Sloan Kettering Cancer Center. Building on his scientific training in epigenetic regulation and experimental hematology, Dr. Chen uncovered and is now investigating the role of SIRT1 and DOT1L interactions in MLL-AF9 leukemia and normal hematopoiesis. His initial achievement identifies cross-inhibitory mechanisms between epigenetic pathways for cancer therapy was recently published in Nature Medicine. His long term goal is to provide novel opportunities for advanced cancer therapies by understanding how epigenetic regulators control gene expression under normal and malignant conditions. Dr. Chen will carry out his proposed project in a stimulating academic environment under the mentorship of Dr. Scott Armstrong, a recognized leader in the fields of leukemia genetics and epigenetics. Dr. Scott A. Armstrong has successfully helped two trainees who have obtained support through the NIH-K99 Career Development Award to obtain tenure-track faculty positions. He has proposed a career development plan to further Dr. Chen's scientific development and to help his transition to independence.
 描述(由申请人提供):尽管已经认识到表观遗传失调在许多类型癌症的发生和进展中起重要作用,但表观遗传癌症治疗的研究主要集中在靶向单一表观遗传调节因子以破坏疾病的维持。决定基因表达/沉默和治疗结果的表观遗传途径之间的交叉对话刚刚开始获得认可。该应用具有直接的临床相关性,因为DOT 1 L抑制剂目前正在对MLL-r白血病患者进行临床试验。已经注意到单独使用DOT 1 L抑制剂治疗的重要临床反应,但毫无疑问,联合方法将是必要的。本申请的目的是确定DOT 1 L抑制后在MLL-r白血病中建立癌基因沉默的关键表观遗传效应子和机制。基于基因组规模RNAi筛选的初步研究已经确定了组蛋白脱乙酰酶Sirtuin 1(SIRT 1)在MLL-AF 9白血病中沉默DOT 1 L依赖性癌基因中的重要作用(发表在Nature Medicine上)。这项拟议的研究将进一步利用全基因组遗传学和表观遗传学研究工具来剖析MLL-r白血病和正常造血中癌基因表达和沉默的表观遗传学机制。在我们看来,拟议的应用是创新的,因为它引入了一种新的组合靶向概念,同时“诱导”和“稳定”表观遗传沉默,以实现深刻的癌基因抑制。此外,这项研究将具有重要意义,因为它通过同时激活癌基因沉默机制,立即为难治性MLL-r白血病提供了新的治疗机会。本提案的具体目标是:1。检查SIRT 1酶活性对MLL-r白血病中DOT 1 L驱动的癌基因沉默的直接影响。2.评估SIRT 1和DOT 1 L联合靶向作为MLL-r白血病新治疗策略的疗效。3.研究SIRT 1在造血干/祖细胞中沉默DOT 1 L依赖性基因的作用。陈春伟大卫博士目前是纪念斯隆凯特琳癌症中心癌症生物学和遗传学系的高级研究科学家。基于他在表观遗传调控和实验血液学方面的科学训练,Chen博士发现并正在研究SIRT 1和DOT 1 L相互作用在MLL-AF 9白血病和正常造血中的作用。他的初步成果确定了癌症治疗的表观遗传途径之间的交叉抑制机制,最近发表在Nature Medicine上。他的长期目标是通过了解表观遗传调节因子如何在正常和恶性条件下控制基因表达,为先进的癌症治疗提供新的机会。陈博士将在白血病遗传学和表观遗传学领域公认的领导者Scott Armstrong博士的指导下,在一个激励人心的学术环境中开展他的拟议项目。Scott A.阿姆斯特朗已经成功地帮助两名学员谁获得了通过NIH-K99职业发展奖的支持,以获得终身教职。他提出了一个职业发展计划,以促进陈博士的科学发展,并帮助他过渡到独立。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chun-Wei David Chen其他文献

Synergistic Efficacy of Dual Menin and PRMT5 Targeting Against <em>NPM1</em> mutated and <em>KMT2A-</em>rearranged Leukemia
  • DOI:
    10.1182/blood-2024-202460
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Nadezda Dolgikh;Johanna Rausch;Marlene Steiner;Jonas Schönfeld;Catharina Lahrmann;Nina Hilke;Maria Alejandra Vila Molerio;Simon Weisemann;Maria Saura-Pañella;Aarón Gallego-Crespo;Matthias Theobald;Daniel Sasca;Chun-Wei David Chen;Michael W.M. Kühn
  • 通讯作者:
    Michael W.M. Kühn
The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax
  • DOI:
    10.1182/blood-2022-167566
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Johanna Rausch;Margarita M. Dzama;Nadezda Dolgikh;Hanna Stiller;Stephan Bohl;Catharina Lahrmann;Kerstin Kunz;Linda Kessler;Hakim Echchannaoui;Chun-Wei David Chen;Thomas Kindler;Francis Burrows;Matthias Theobald;Daniel Sasca;Scott A. Armstrong;Michael Kuehn
  • 通讯作者:
    Michael Kuehn
Synergistic Efficacy of Dual Menin and PRMT5 Targeting Against emNPM1/em mutated and emKMT2A-/emrearranged Leukemia
靶向Menin和PRMT5双重作用对NPM1突变和KMT2A重排白血病的协同疗效
  • DOI:
    10.1182/blood-2024-202460
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Nadezda Dolgikh;Johanna Rausch;Marlene Steiner;Jonas Schönfeld;Catharina Lahrmann;Nina Hilke;Maria Alejandra Vila Molerio;Simon Weisemann;Maria Saura-Pañella;Aarón Gallego-Crespo;Matthias Theobald;Daniel Sasca;Chun-Wei David Chen;Michael W.M. Kühn
  • 通讯作者:
    Michael W.M. Kühn
A Novel Form of AEBP2-Containing PRC2.2 Is a Genetic Dependency in Germinal Centre B-Cell Lymphoma and Its Targeting Can Overcome Acquired Resistance to EZH2 Inhibition
  • DOI:
    10.1182/blood-2024-205382
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    James Nolan;Daniel Angelov;Darragh Nimmo;Gráinne Holland;Molly Davies;Eugene Dillon;David Reck;Craig Monger;Chun-Wei David Chen;Gerard L Brien;Elisabeth Vandenberghe;Eric Conway;Adrian Bracken
  • 通讯作者:
    Adrian Bracken
COX4I1 Controls Mitochondrial Electron Transport Chain Complex IV Assembly and Leukemia Progression in Acute Myeloid Leukemia
  • DOI:
    10.1182/blood-2023-188526
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Leisi Zhang;Mingli Li;Anthony KN Chan;Qiao Liu;Hyunjun Kang;Sheela Pangeni Pokharel;Nicole Mattson;Priyanka Singh;Lu Yang;Chun-Wei David Chen
  • 通讯作者:
    Chun-Wei David Chen

Chun-Wei David Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chun-Wei David Chen', 18)}}的其他基金

Mechanism and therapeutic opportunities of targeting the Tudor domain
针对 Tudor 结构域的机制和治疗机会
  • 批准号:
    10606365
  • 财政年份:
    2022
  • 资助金额:
    $ 24.9万
  • 项目类别:
Integrative Analyses of Saturation CRISPR Protein Scan
饱和 CRISPR 蛋白质扫描的综合分析
  • 批准号:
    10058930
  • 财政年份:
    2019
  • 资助金额:
    $ 24.9万
  • 项目类别:
Role of BAZ2A in MLL-r leukemia and therapeutic response
BAZ2A 在 MLL-r 白血病中的作用和治疗反应
  • 批准号:
    10593927
  • 财政年份:
    2019
  • 资助金额:
    $ 24.9万
  • 项目类别:
Role of BAZ2A in MLL-r leukemia and therapeutic response
BAZ2A 在 MLL-r 白血病中的作用和治疗反应
  • 批准号:
    10356863
  • 财政年份:
    2019
  • 资助金额:
    $ 24.9万
  • 项目类别:
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia
针对混合谱系白血病前馈表观遗传回路的组合
  • 批准号:
    10306337
  • 财政年份:
    2018
  • 资助金额:
    $ 24.9万
  • 项目类别:
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia
针对混合谱系白血病前馈表观遗传回路的组合
  • 批准号:
    10531876
  • 财政年份:
    2018
  • 资助金额:
    $ 24.9万
  • 项目类别:
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia
针对混合谱系白血病前馈表观遗传回路的组合
  • 批准号:
    10059184
  • 财政年份:
    2018
  • 资助金额:
    $ 24.9万
  • 项目类别:
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
MLL重排白血病癌基因沉默的表观遗传机制
  • 批准号:
    9324564
  • 财政年份:
    2016
  • 资助金额:
    $ 24.9万
  • 项目类别:

相似海外基金

Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
  • 批准号:
    2335802
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
  • 批准号:
    2335801
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
A Longitudinal Study of the Relationship between Participation in a Comprehensive Exercise Program and Academic Achievement
参加综合锻炼计划与学业成绩之间关系的纵向研究
  • 批准号:
    24K14615
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Collaborative Research: Characterizing Best Practices of Instructors who Have Narrowed Performance Gaps in Undergraduate Student Achievement in Introductory STEM Courses
合作研究:缩小本科生 STEM 入门课程成绩差距的讲师的最佳实践
  • 批准号:
    2420369
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
Collaborative Research: Using Adaptive Lessons to Enhance Motivation, Cognitive Engagement, And Achievement Through Equitable Classroom Preparation
协作研究:通过公平的课堂准备,利用适应性课程来增强动机、认知参与和成就
  • 批准号:
    2335800
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
WTG: Diffusion of Research on Supporting Mathematics Achievement for Youth with Disabilities through Twitter Translational Visual Abstracts
WTG:通过 Twitter 翻译视觉摘要传播支持残疾青少年数学成就的研究
  • 批准号:
    2244734
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
The Impact of Emotional Experiences of Pride on Long-Term Goal Achievement Behaviors in Elite Athletes
骄傲的情感体验对优秀运动员长期目标实现行为的影响
  • 批准号:
    23K16740
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Meta-Analysis of the Instructional-Relational Model of Student Engagement and Math Achievement: A Moderation and Mediation Approach
学生参与度和数学成绩的教学关系模型的元分析:一种调节和中介方法
  • 批准号:
    2300738
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
Improving maths achievement in children with speech, language, and communication needs through 'collaborative vocabulary teaching'
通过“协作词汇教学”提高有言语、语言和交流需求的儿童的数学成绩
  • 批准号:
    2890475
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Studentship
HSI Institutional Transformation Project: Retention and Achievement for Introductory STEM English Learners (RAISE)
HSI 机构转型项目:STEM 英语入门学习者的保留和成就 (RAISE)
  • 批准号:
    2225178
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了